- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03127319
A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases
January 14, 2018 updated by: Aimin Zang, Affiliated Hospital of Hebei University
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus docetaxel and zoledronic versus docetaxel and zoledronic alone as second line treatment for advanced non-squamous non-small cell lung cancer with bone metastases.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hebei
-
BaoDing, Hebei, China
- Recruiting
- Affiliated Hospital of Hebei University
-
Contact:
- Aimin Zang
- Phone Number: 13930881628
- Email: 15175292891@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 71 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age:18 to 75 years old (man or female)
- Pathologically diagnosed with metastatic or recurrent non-squamous non-small cell lung cancer
- Patients with at least one evaluate lesions of the lung and bone metastases.(measuring≥10mm on spiral CT scan, satisfying the criteria in RECIST1.1 and WHO)
- Refractory or failure of prior therapy
- Life expectancy greater than or equal to 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Major organ function has to meet the following criteria:
For results of blood routine test (without blood transfusion within 14 days)
- HB≥90g/L
- ANC≥1.5×109/L
- PLT≥180×109/L
For results of blood biochemical test:
- TBIL<1.5×ULN;
- ALT and AST<2.5×ULN, but< 5×ULN if the transferase elevation is due to liver metastases;
- Serum creatinine ≤1.25×ULN , or calculated creatinine clearance>45 ml/min(per the Cockcroft-Gault formula);
- Women of childbearing age must have contraceptive measures or have test pregnancy (serum or urine) enroll the study before 7 days, and the results must be negative, and take the methods of contraception during the test and the last to have drugs after 8 weeks. Men must be contraception or has sterilization surgery during the test and the last to have drugs after 8 weeks;
- Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up.
Exclusion Criteria:
- Allergic to apatinib and docetaxel;
- Have high blood pressure and antihypertensive drug treatment can not control (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg), with class Ⅱ and above coronary heart disease, arrhythmia (including QTc lengthened men > 450 ms, women > 470 ms) and class Ⅲ-Ⅳ cardiac insufficiency;
- A variety of factors influencing oral drugs (such as unable to swallow, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.).
- Patients with tendency of gastrointestinal bleeding, including the following: a local active ulcerative lesions, and defecate occult blood (+ +); Has melena and hematemesis in two months; For defecate occult blood (+) and primary lesions without surgical removal of the stomach tumor, requirement of gastroscopy, such as ulcer type of gastric cancer, and researchers think that may be gastrointestinal hemorrhage;
- Coagulant function abnormality (INR > 1.5 ULN, APTT > 1.5 ULN), with bleeding tendency.
- Patients with symptoms of central nervous system metastasis.
- Pregnant or lactating women.
- history of psychiatric drugs abuse and can't quit or patients with mental disorders.
- Less than 4 weeks from the last clinical trial.
- The researchers think inappropriate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: apatinib and docetaxel zoledronic
apatinib 500mg qd po; docetaxel 60mg/m² iv q3w; zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
|
apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
|
|
Active Comparator: docetaxel zoledronic
docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
|
docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression free survival
Time Frame: evaluation per 2 cycles (6 weeks)
|
evaluation per 2 cycles (6 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: evaluation per 2 cycles (6 weeks)
|
evaluation per 2 cycles (6 weeks)
|
|
|
DCR (Disease control rate)
Time Frame: evaluation per 2 cycles (6 weeks)
|
evaluation per 2 cycles (6 weeks)
|
|
|
ORR (Objective response rate)
Time Frame: evaluation per 2 cycles (6 weeks)
|
evaluation per 2 cycles (6 weeks)
|
|
|
SREs(Skeletal-related events)
Time Frame: evaluation per 2 cycles (6 weeks)
|
measured pain, a fracture, the need for bone radiation or surgical therapy, spinal cord compression, or hypercalcemia
|
evaluation per 2 cycles (6 weeks)
|
|
Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
Time Frame: evaluation per 2 cycles (6 weeks)
|
evaluation per 2 cycles (6 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 3, 2017
Primary Completion (Anticipated)
April 1, 2019
Study Completion (Anticipated)
December 1, 2019
Study Registration Dates
First Submitted
December 30, 2016
First Submitted That Met QC Criteria
April 20, 2017
First Posted (Actual)
April 25, 2017
Study Record Updates
Last Update Posted (Actual)
January 17, 2018
Last Update Submitted That Met QC Criteria
January 14, 2018
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protein Kinase Inhibitors
- Docetaxel
- Apatinib
Other Study ID Numbers
- AHHU-2017AMZ01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.